The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing ...

A once-daily oral pill helped people with obesity lower their weight by an average of 12% after 72 weeks, according to manufacturer Eli Lilly. Dr. Sue Decotiis, a weight-loss doctor in New York City, ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

• How McDonald’s, Uber and Pfizer fared as they updated the market • How Airbnb disappointed with its latest update ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...